Computer Billing Standard

Publication
Article
OncologyONCOLOGY Vol 14 No 10
Volume 14
Issue 10

Physicians will have to use the “ANSI ASC X12N” electronic transmission format whenever they do computerized billing.

Physicians will have to use the “ANSI ASC X12N” electronic transmission format whenever they do computerized billing. The theory is that by using a single format (ANSI is the American National Standards Institute) instead of any of the 400 or so different ones kicking around today that a health plan might mandate, life will be simpler for physicians, and practice costs will decline precipitously. Medical practices with annual receipts over $5 million must be ANSI-compliant by October 2002. Those under that ceiling have until October 2003.

Articles in this issue
Computer Technology Helps Radiologists Spot Overlooked Small Breast Cancers
New Awards Spotlight Courage of Cancer Survivors
Using the Body’s Anticancer Defenses to Guide and Improve Breast Cancer Treatment
Vaccine Studies Demonstrate Promise of Immunotherapy to Treat Breast Cancer and Prevent Recurrence
Children’s Art Project at M. D. Anderson Cancer Center
Settling on an Increased NCI Budget
Computer Billing Standard
Ligand Receives FDA Marketing Clearance for Bexarotene Gel
Mayo Clinic Study Shows Patients Uncertain About Cancer Risk Terms
Multidisciplinary Management of Pediatric Soft-Tissue Sarcoma
Follow-up Care for Cancer: Making the Benefits Equal the Cost
Commentary (Stenson): Indications for Selective Neck Dissection: When, How, and Why
Follow-up Care for Cancer: Making the Benefits Equal the Cost
Costs of Smoking Among Active-Duty US Air Force Personnel—United States, 1997
Multidisciplinary Management of Pediatric Soft-Tissue Sarcoma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content
Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.